The FDA has updated the labeling for Camzyos to reduce echocardiogram monitoring requirements for patients in the maintenance phase and contraindications.

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...

SaveHealth assesses the relative benefits of Zoloft vs. Lexapro, comparing their usage, effectiveness, tolerability, ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

CYP3A4 breaks down drugs that treat various health conditions, including the anti-cancer agent paclitaxel and COVID-19 therapeutic nirmatrelvir. CYP3A4 inhibitors are commonly co-administered to ...

Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States Department of Biochemistry and Biophysics, The University of ...